Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16441939 | 0.93 | LMNA (0.40) | OGAMMP9MMP12LMNAKMT2A | |
| SCHEMBL21518245 | 0.90 | LMNA (0.45) | OGAMMP9MMP12LMNAKMT2A | |
| SCHEMBL20299969 | 0.84 | MMP9 (0.40) | OGAMMP9MMP12LMNAKMT2A | |
| SCHEMBL17932937 | 0.83 | OGA (0.41) | OGAMMP9MMP12LMNAKMT2A | |
| SCHEMBL21518247 | 0.83 | LMNA (0.49) | OGAMMP9MMP12LMNAKMT2A | |
| SCHEMBL24645816 | 0.82 | LMNA (0.48) | MMP9MMP12LMNAKMT2APOLB | |
| SCHEMBL24699769 | 0.82 | LMNA (0.48) | MMP9MMP12LMNAKMT2APOLB | |
| SCHEMBL10903487 | 0.81 | CA9 (0.41) | OGAMMP9MMP12LMNAKMT2A | |
| SCHEMBL10903484 | 0.81 | CA9 (0.41) | OGAMMP9MMP12LMNAKMT2A | |
| SCHEMBL17230163 | 0.81 | LMNA (0.53) | MMP9MMP12LMNAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038687-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | GENEVANT SCIENCES GMBH (CH) | 2023-02-09 | — | — | US | disclosed |
| US-20180221402-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | ROIVANT SCIENCES LTD. (GB) | 2018-08-09 | — | — | US | disclosed |
| WO-2016118697-A9 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016118697-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | PHASERX, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160206750-A1 | BLOCK COPOLYMERS | ROIVANT SCIENCES LTD. (GB) | 2016-07-21 | — | — | US | disclosed |
| WO-2015017519-A1 | BLOCK COPOLYMERS AND THEIR CONJUGATES OR COMPLEXES WITH OLIGONUCLEOTIDES | PHASERX, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038687-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | CD63, LIPA, NPC1L1 | OGA 1915/4885MMP9 2240/4885MMP12 1222/4885 |
| US-20160206750-A1 | BLOCK COPOLYMERS | CHMP4B, CD47, EEA1 | OGA 3083/4885MMP9 4350/4885MMP12 1869/4885 |
| US-20180221402-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | CD63, LIPA, NPC1L1 | OGA 1915/4885MMP9 2240/4885MMP12 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.